JD Supra5h
Teva Announces New Biosimilar Deals
Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...
Yahoo Finance18d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS ...
Financial Post18d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to ...
Nasdaq18d
Samsung Bioepis and Teva Pharmaceutical Enter Partnership for EPYSQLI® Biosimilar to Enhance Treatment Options for Rare Disease Patients in the U.S.
EPYSQLI's approval by the FDA represents a milestone for Teva, potentially increasing revenue and market share in the fast-growing biosimilars market. Teva's commercial responsibilities for ...